Lundbeckfonden Ventures-backed Trevi has filed for an $86.2m IPO to fund clinical trials for pruritus-focused drug treatments.

Trevi Therapeutics, the US-based pruritus treatment developer backed by pharmaceutical firm Lundbeck, has filed to raise up to $86.2m in an initial public offering. Founded in 2011, Trevi is developing an oral therapy called Nalbuphine ER, which is designed to treat a severe form of itching called pruritus in addition to chronic coughing caused by…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.